Personalised mRNA vaccines are showing potential as a treatment for some patients with pancreatic cancer, with clinical trial findings documenting sustained immune responses and long-term remission among certain participants.
The research, conducted at Memorial Sloan Kettering Cancer Center, explored how patients’ immune systems could be trained to recognise and attack cancer cells carrying specific mutations.
Standard treatment for pancreatic cancer generally involves surgery and chemotherapy. The experimental approach seeks to complement existing treatment by developing a vaccine tailored to the genetic characteristics of each patient’s tumour.
How Personalised mRNA Cancer Vaccines Work
Unlike conventional vaccines designed to prevent infectious diseases, the mRNA treatments are developed to target existing cancer cells.
The process begins with a biopsy, which provides a sample of the patient’s tumour. Researchers then use genomic analysis and artificial intelligence to identify the specific mutations present in the cancer.
The findings are used to develop a customised mRNA sequence designed to teach the immune system to recognise the abnormal proteins produced by cancer cells.
Once administered, the vaccine stimulates the production of immune cells capable of identifying and attacking the targeted cancer cells.
Trial Records Immune Response in Half of Participants
A small clinical trial involving 16 patients with pancreatic cancer found that the personalised vaccine produced a measurable response in eight participants.
Among those who responded was Donna Gustafson, whose immune response reportedly increased by 10,000 times following vaccination.
Researchers also found that the immune response remained detectable for years after the final vaccine dose, indicating that the effects could be sustained over an extended period.
The findings have contributed to research into the potential use of personalised immunotherapy for pancreatic cancer.
Access Remains Limited to Clinical Trials
Despite the reported results, personalised mRNA cancer vaccines are not yet widely available to patients.
Access is currently restricted largely to clinical trials and specialised research institutions. Patients must meet specific eligibility requirements and secure a place in studies conducted by medical professionals and researchers.
Donna Gustafson’s treatment involved participation in a clinical trial led by specialists, including surgeon and scientist Dr Vinod Balachandran.
The development process also presents financial and logistical challenges. Each vaccine must be designed specifically for an individual patient’s tumour, requiring advanced laboratory facilities and specialised genetic analysis.
These requirements make large-scale production and widespread access difficult at present.
Cancer Research Expands to Other Types of Tumours
The National Cancer Institute is working with private companies to accelerate the development and production of mRNA vaccines targeting a wider range of cancers.
The research includes potential applications involving skin, lung, kidney and bladder cancers.
The collaboration is intended to advance the development of personalised treatments and expand research beyond the cancers currently being investigated in clinical studies.
Researchers Compare mRNA Vaccines With Conventional Treatments
The potential benefits of personalised mRNA vaccines are also being examined in relation to the side effects associated with conventional cancer treatments.
Chemotherapy can produce significant systemic side effects and often involves demanding treatment schedules. By comparison, the mRNA injections used in the reported pancreatic cancer trial were associated with minimal or no significant side effects.
Separate research by Merck and Moderna involving skin cancer has also reported promising results. Their findings showed a 42% reduction in the risk of recurrence or death over a two-year period among patients receiving the experimental treatment approach.
These findings provide additional evidence being examined by researchers investigating the use of mRNA technology against different forms of cancer.
Widespread Availability Remains a Challenge
Although clinical research has demonstrated the potential of personalised mRNA vaccines, the treatments remain experimental and are not yet a standard option for the wider population of pancreatic cancer patients.
Approximately 70,000 Americans are diagnosed with pancreatic cancer annually, highlighting the number of people who could potentially benefit if the technology becomes more widely accessible.
For now, access depends on participation in clinical trials and the availability of specialised research facilities. Researchers continue working to address the production costs and technical requirements that currently limit the use of personalised cancer vaccines.
